Alder Biopharmaceuticals Inc. Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced results from a Phase 1 clinical study of the Company’s lead monoclonal antibody therapeutic, ALD518, for treatment of advanced cancer demonstrating the drug to be safe, well-tolerated and to reduce fatigue in patients with advanced cancer. Data were presented during a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. (ASCO Abstract No. 3025)